peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

The Annual General Meeting of Hansa Medical has been rescheduled to May 6, 2013

21 Mar 2013, 08:00
Regulatory information

The Board of Hansa Medical has resolved to reschedule the Annual General Meeting (AGM) from May 7 to May 6, 2013 at 17:00 in Hörsalen at Scheelevägen 22 in Lund. A separate Notice of the AGM will be published at the latest on April 2, 2013.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.